



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

28<sup>th</sup> December, 2021

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
"Exchange Plaza", Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051


Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for your information.

Thanking you

Yours faithfully  
For NATCO Pharma Limited  
  
M. Adinarayana  
Company Secretary &  
Vice President (Legal and Corp Affairs )

Encl : as above



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/19/2021-2022

## NATCO receives approval for the drug for the treatment of Covid-19 in India

**Hyderabad, India, December 28<sup>th</sup>, 2021**

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has received approval for Covid 19 drug Molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT<sup>®</sup>. Molnupiravir is the first Covid drug authorized by Drugs Controller General (India) (DCGI) for the treatment of Covid 19 infection with SpO<sub>2</sub>>93% and who have high risk of progression of the disease including hospitalization or death. This capsule was earlier approved in United Kingdom and United States of America.

MOLNUNAT will be marketed by Natco and will be priced affordably. Molnupiravir is the first Covid drug available in Indian market with a minimal dosage duration of 5 days with promising viral clearance. Phase 3 trials of Molnupiravir has shown significant reduction in hospitalization of Covid 19 patients.

MOLNUNAT is expected to be launched this week by Natco in the Indian market.

Forwarded for favour of publication  
For NATCO Pharma Limited

A handwritten signature in blue ink, appearing to read "M Adinarayana".

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)